Residency · Residency · Psychiatry
First-Episode Psychosis: Early Intervention Models
The Importance of Early Intervention
Duration of Untreated Psychosis (DUP)
DUP is defined as the time from onset of frank psychotic symptoms to initiation of adequate antipsychotic treatment. Average DUP in the United States: 1-3 years. Longer DUP is consistently associated with poorer outcomes: lower remission rates, more severe negative symptoms, greater functional impairment, poorer quality of life. The relationship between DUP and outcomes appears to be dose-dependent -- every additional month of untreated psychosis worsens prognosis. Reducing DUP through education and early detection programs is a major public health priority. The "critical period" hypothesis (Birchwood): the first 2-5 years after psychosis onset represent a window of greatest therapeutic opportunity.
Prodromal Phase
The clinical high-risk (CHR) or attenuated psychosis syndrome precedes frank psychosis in many patients. Symptoms: attenuated positive symptoms (unusual perceptual experiences, suspiciousness), cognitive decline, social withdrawal, functional deterioration. Conversion rate from CHR to psychosis: approximately 20-35% over 2-3 years. Screening tools: Structured Interview for Psychosis-Risk Syndromes (SIPS), Comprehensive Assessment of At-Risk Mental States (CAARMS) Management of CHR: psychotherapy (CBT), psychosocial support, close monitoring; antipsychotic treatment is NOT recommended at the CHR stage unless conversion occurs.
Coordinated Specialty Care (CSC) Programs
The RAISE-ETP Model (Recovery After an Initial Schizophrenia Episode -- Early Treatment Program)
The landmark NIMH-funded study that established the CSC model in the United States. NAVIGATE program: comprehensive team-based intervention including: Individualized medication management: low-dose antipsychotic prescribing with shared decision-making. Family psychoeducation: FAMILY (Family-Aided Assertive Community Treatment) or similar models. Individual resiliency training (IRT): CBT-based psychotherapy. Supported employment and education (SEE): helping patients maintain work or school. Results: RAISE-ETP showed significantly better quality of life, symptom improvement, and functional outcomes compared to usual care at 2 years. Led to SAMHSA's Community Mental Health Block Grant set-aside for first-episode psychosis programs (10% of state mental health funds) Examples of CSC programs: OnTrackNY, NAVIGATE, EASA (Early Assessment and Support Alliance)
Key Components of CSC
Low-dose antipsychotic treatment: start low, go slow; minimize side effects that drive non-adherence. Individual therapy: CBT for psychosis (CBTp) or similar evidence-based approach. Family involvement: psychoeducation, communication training, problem-solving skills. Supported employment/education: evidence-based vocational rehabilitation (Individual Placement and Support model) Case management: coordination of care, housing support, crisis intervention. Peer support: integration of individuals with lived experience of psychosis. Substance use treatment: integrated dual-disorder treatment.
Pharmacotherapy in First-Episode Psychosis
Low-Dose Antipsychotic Initiation
First-episode patients are more sensitive to both therapeutic effects and side effects of antipsychotics. Start at 50% of the dose typically used for chronic schizophrenia. Second-generation antipsychotics (SGAs) preferred as first-line due to lower EPS risk:
| Agent | FEP Dose Range | Chronic Schizophrenia Dose | Metabolic Risk | Key Advantages |
|---|---|---|---|---|
| Aripiprazole | 5-15 mg/day | 10-30 mg/day | Low | Lowest metabolic risk; partial D2 agonism |
| Risperidone | 1-3 mg/day | 2-6 mg/day | Moderate | Well-studied; LAI available |
| Paliperidone | 3-6 mg/day | 6-12 mg/day | Moderate | No hepatic metabolism; LAI options |
| Quetiapine | 300-500 mg/day | 400-800 mg/day | Moderate-High | Sedating (useful for insomnia); low EPS |
| Olanzapine | Avoid as first-line | 10-20 mg/day | High | Effective but metabolic risk limits use in FEP |
Avoid olanzapine as first-line in first-episode due to high metabolic risk (weight gain, diabetes) Clozapine should be considered after failure of two adequate antipsychotic trials.
Response and Duration of Treatment
~70-80% of first-episode patients respond to antipsychotic treatment (much higher than chronic schizophrenia) Time to response: typically 2-4 weeks, but may take up to 6-8 weeks. Duration of antipsychotic treatment after first episode is debated: Guidelines generally recommend at least 1-2 years of maintenance treatment. Relapse rates after discontinuation are high (~80% within 1-2 years vs. ~20-30% with continued treatment) Some patients (10-20%) may maintain remission after supervised, gradual discontinuation. Long-acting injectable antipsychotics are increasingly advocated in first-episode psychosis to prevent covert non-adherence and relapse.
Metabolic Monitoring
Baseline and ongoing monitoring essential: weight, BMI, waist circumference, fasting glucose, HbA1c, lipid panel, blood pressure. Monitor at baseline, 1 month, 3 months, then every 6-12 months. Lifestyle interventions (diet, exercise) should be started concurrently with antipsychotic initiation. Switch antipsychotic if significant metabolic adverse effects develop.
Family Psychoeducation
Rationale
Families are essential partners in recovery. Expressed emotion (EE) -- critical comments, hostility, emotional over-involvement -- is associated with higher relapse rates. Family psychoeducation reduces relapse rates by 50% compared to standard care. Key components: illness education, communication skills training, problem-solving, crisis management, emotional support for family members. Models: McFarlane's multifamily group psychoeducation, Falloon's behavioral family therapy.
Supported Employment and Education
Individual Placement and Support (IPS)
Evidence-based model of supported employment for serious mental illness. Core principles: rapid job search (no "train then place"), competitive employment, integration with mental health treatment, attention to patient preferences, ongoing support. Consistently shows 2-3x higher employment rates compared to traditional vocational rehabilitation. Early application in first-episode psychosis helps patients maintain their developmental trajectory (school, career)
<image> A diagram of the Coordinated Specialty Care (CSC) team model for first-episode psychosis. Show a central hub with the patient at the center, surrounded by spokes connecting to each team component: prescriber (low-dose medication management), individual therapist (CBTp/IRT), family therapist (psychoeducation), supported employment/education specialist, case manager, and peer support specialist. Include arrows showing bidirectional communication between team members. Label each spoke with the specific evidence-based intervention. Include outcomes data from the RAISE-ETP trial. Clean organizational diagram. </image>
<image> A timeline showing the progression from prodromal phase to first-episode psychosis and the impact of duration of untreated psychosis (DUP). Show a horizontal timeline with markers for: premorbid functioning, prodromal symptoms (attenuated positive symptoms, functional decline), onset of frank psychosis (threshold crossing), DUP period, and treatment initiation. Below the timeline, show outcome curves: shorter DUP leads to better trajectory, longer DUP leads to worse trajectory. Include the "critical period" window (first 2-5 years). Annotate with evidence for DUP-outcome relationship. </image>
<image> A dosing comparison chart for antipsychotics in first-episode vs. chronic schizophrenia. Show the recommended dose ranges for aripiprazole, risperidone, paliperidone, quetiapine, and olanzapine in first-episode patients (lower range) vs. chronic patients (standard range). Use horizontal bars with the first-episode range highlighted and the full standard range shown for comparison. Include metabolic risk ratings and EPS risk ratings for each agent. Clean clinical reference format. </image>
Clinical Pearls
First-episode psychosis patients respond to much lower doses of antipsychotics than chronic patients -- starting at standard chronic schizophrenia doses causes unnecessary side effects and drives non-adherence. Reducing the duration of untreated psychosis is one of the most important modifiable factors in long-term prognosis -- every month of delay matters. Coordinated specialty care programs produce superior outcomes to treatment-as-usual and are now funded in every US state through SAMHSA block grants. Family psychoeducation reduces relapse by ~50% and is among the most potent interventions in psychosis care -- yet it is consistently underutilized. Metabolic monitoring must begin at the moment of antipsychotic initiation, not after problems develop -- young patients are at particular risk for metabolic syndrome. Do not diagnose schizophrenia at first episode -- use "first-episode psychosis" or "schizophreniform disorder" until the 6-month criterion is met. Consider long-acting injectable antipsychotics early in treatment (not just after repeated relapses) -- preventing the first relapse may be more important than treating subsequent ones.
References
- Kane JM, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2016;173(4):362-372.
- Correll CU, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018;75(6):555-565.
- Perkins DO, et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 2005;162(10):1785-1804.
- Dixon LB, et al. Implementing coordinated specialty care for early psychosis: the RAISE Connection Program. Psychiatr Serv. 2015;66(7):691-698.
- McGorry PD, et al. Early intervention in psychosis: concepts, evidence, and future directions. World Psychiatry. 2008;7(3):148-156.
